Clinical trials: Ejection Fraction
Heart Failure of Reduced Ejection Fraction (HFrEF)
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
- Trial name
- NCT07044700
- Testing
- Jardiance, non-SGLT2 inhibitors
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Boehringer Ingelheim
HFrEF - Heart Failure With Reduced Ejection Fraction
Effect of Vericiguat on cardiAc Remodeling in Patients With Heart faiLure and Reduced Ejection fractioN (HFrEF): A Prospective sTudy usIng NOvel Echocardiographic Imaging Techniques (VALENTINO)
The biological process that underlies the pathogenesis of heart failure (HF) is termed cardiac remodeling. Pathological cardiac remodeling includes structural and functional change of the heart.
- Trial name
- NCT07472595
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD
The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Ischemic Heart Disease
- Trial name
- NCT03780803
- Testing
- home cardiac rehabilitation and respiratory rehabilitation
- Where
- Poland
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood…
- Trial name
- EAT HFpEF (NCT06768437)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University of Leicester
Heart Failure With Reduced Ejection Fraction, Ischemic Cardiomyopathy
Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.
- Trial name
- RESTORE-PCI (NCT05828719)
- Testing
- Percutaneous coronary intervention
- Where
- South Korea
- Volunteers
- 900 people
- Sponsor
- Samsung Medical Center
Heart Failure With Reduced Ejection Fraction, Left Bundle-Branch Block
Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB
The present study will randomize 50 symptomatic heart failure patients with severely reduced left ventricular ejection fraction (LVEF) and a true left bundle branch block to either direct HIS-pacing or biventricular pacing and…
- Trial name
- HISalternative (NCT03614169)
- Testing
- Implantation of a HIS-pacing lead, Implantation of a LV-pacing lead
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Failure
AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure
To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) in a Phase 3…
- Trial name
- FLOURISH (NCT03360448)
- Testing
- Ad5.hAC6
- Sponsor
- Renova Therapeutics
Heart Failure, Mortality
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice.
- Trial name
- PARADE-HF (NCT05329727)
- Testing
- Angiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
- Where
- South Korea
- Volunteers
- 1,000,000 people
- Sponsor
- Wonju Severance Christian Hospital
Renal Insufficiency, Chronic, Heart Failure With Preserved Ejection Fraction
Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction
The purpose of this study is to investigate the role of mitochondrial derived oxidative stress on exercise capacity and arterial hemodynamics in HFpEF patients with and without chronic kidney disease.
- Trial name
- NCT03960073
- Testing
- MitoQ
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
Heart Failure, Cardiomyopathy, Dilated
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
- Trial name
- CorCinch-HFrEF (NCT03533517)
- Testing
- AccuCinch® Ventricular Restoration
- Where
- 18 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ancora Heart, Inc.
Heart Failure With Preserved Ejection Fraction, Sarcopenia
Effectiveness of a Cardiac Rehabilitation Program in Elderly Patients With Heart Failure.
The main objective of the study is to assess the effectiveness of a cardiac rehabilitation program on functionality, measured by kinematic analysis, cardiorespiratory capacity, and ventricular ejection fraction in elderly…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Sarcopenia, Frail Elderly Syndrome, Comorbidities and Coexisting Conditions
- Trial name
- FUNNEL+ (NCT05393362)
- Testing
- Cardiac Rehabilitation Program (CR), Control Group (CG)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- University of Malaga
Chronic Heart Failure, Reduced Ventricular Ejection Fraction
CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF.
- Trial name
- CHF-COVReduced (NCT05089162)
- Testing
- Clinical examination centered on congestion, Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds, Blood sample retrieved for biological assessment and biobanking
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Pr. Nicolas GIRERD
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Myocardial Remodeling
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
The goal of this project is to investigate the effects that the addition of aldosterone blockade with eplerenone will have on the progression of diastolic dysfunction in patients with controlled essential hypertension.
- Trial name
- Aldosterone (NCT00980031)
- Testing
- Eplerenone, Lactose Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Creighton University
Heart Failure, Microvascular Angina
Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology
This study aims to evaluate the incidence of coronary microvascular dysfunction (CMD) and its prognostic implication for the improvement of left ventricular function in patients who have been diagnosed with heart failure with…
- Conditions
- Heart Failure, Microvascular Angina, Non-ischemic Cardiomyopathy
- Trial name
- HFrEF-CMD (NCT06243653)
- Testing
- CMD test
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Coronary Microvascular Dysfunction, Heart Failure With Preserved Ejection Fraction (HFpEF)
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
The purpose of this study is to examine small vessel disease (a condition in which the small arteries in the heart become narrowed).
- Trial name
- NCT03876223
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Cedars-Sinai Medical Center
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Heart Failure
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection…
- Trial name
- Aliskiren (NCT00982033)
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Wake Forest University Health Sciences
Heart Failure With Reduced Ejection Fraction
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
- Trial name
- VANGUARD (NCT02113033)
- Testing
- Equilia® Vagal Nerve Stimulation
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 15 people
- Sponsor
- LivaNova
Myocardial Infarction, Left Ventricular Remodeling
Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling
Purpose: The purpose of this study is to evaluate the impact of circulating miR-126 on left ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation…
- Conditions
- Myocardial Infarction, Left Ventricular Remodeling, miR-126
- Trial name
- PMIR-miR-126 (NCT01875484)
- Where
- 17 sites in China
- Volunteers
- 1,200 people
- Sponsor
- Qilu Hospital of Shandong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.